Buy 5 or More Products! Save 25% On Total.
 Buy 3 or More Products! Save 10% On Total.
 Free Shipping! No Minimum Order.

Which of the following information is/are TRUE about Nexletol? [Select All That Apply]
a. An active ingredient found in Nexletol is Bempedoic acid.
b. It is indicated for reducing the elevated LDL-c level.
c. It is an ATP Citrate Lyase (ACL) inhibitor.
d. The recommended dose should be taken every 8 hours.
e. Hyperuricemia and increased risk of tendon rupture or injury is reported side effect of the drug.
Answer: (a, b, c, and e).  
The active ingredient found in Nexletol is Bempedoic acid. It is a tablet, an oral, once-daily, non-statin  (LDL-C) lowering medicine.
It is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.  
Nexletol is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.
Nexletol was generally well-tolerated in clinical studies. Label warnings and precautions include hyperuricemia, with the development of gout in a small percentage of patients, as well as increased risk of tendon rupture or injury.
Overall in Phase 3 studies, the adverse events reported most frequently in patients who received Nexletol were generally reported at similar rates in patients who received placebo.
The most common adverse events reported with Nexletol (incidence ≥ 2% and greater than placebo) were upper respiratory tract infections, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.
Avoid concomitant use of Nexletol with Simvastatin greater than 20 mg.